# Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer

> **NCT04032418** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Roswell Park Cancer Institute** · enrollment: 9 (actual)

## Conditions studied

- Lung Non-Small Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04032418
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-13
- **Primary completion:** 2025-03-14
- **Final completion:** 2026-06-14
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04032418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04032418, "Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-08-14 from https://api.ai-analytics.org/clinical/NCT04032418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*